Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.30 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.30 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28711889 | 0.93 | ALDH1A1 (0.35) | ALDH1A1CNR1CNR2 | |
| SCHEMBL28961623 | 0.87 | ALDH1A1 (0.35) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL29654526 | 0.85 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25486764 | 0.85 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL8959151 | 0.84 | LPAR1 (0.35) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL22873988 | 0.82 | LPAR1 (0.34) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL8959178 | 0.82 | LPAR1 (0.34) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL20026318 | 0.82 | LPAR1 (0.34) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL8959138 | 0.82 | LPAR1 (0.34) | ALDH1A1CNR1CNR2LPAR6LPAR1 | |
| SCHEMBL5433812 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020240392-A1 | PROCESS FOR PREPARATION OF PYROXASULFONE | PI INDUSTRIES LIMITED (IN) | 2020-12-03 | — | — | WO | disclosed |
| US-8895068-B2 | Nanoparticle composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889103-B2 | Diagnostic agent composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110124593-A1 | Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PHAX, PIK3CA | ALDH1A1 4843/4885CNR1 2113/4885CNR2 1651/4885 |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PIK3CA, PTEN | ALDH1A1 4846/4885CNR1 3909/4885CNR2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.